Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Multiple Myeloma 70Leukemia, Myeloid, Acute 70Lymphoma, Large B-Cell, Diffuse 61Lymphoma, Non-Hodgkin 58Leukemia, Lymphocytic, Chronic, B-Cell 57Lymphoma 56Melanoma 52Leukemia 52Breast Neoplasms 49Burkitt Lymphoma 48Myelodysplastic Syndromes 44Recurrence 41Lymphoma, Follicular 41Lymphoma, B-Cell 38Lymphoma, Mantle-Cell 37Ovarian Neoplasms 32Neuroblastoma 32Lymphoma, B-Cell, Marginal Zone 27Sarcoma 26Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Hodgkin Disease 24Neoplasm Metastasis 23Triple Negative Breast Neoplasms 18Carcinoma, Renal Cell 18Neoplasms, Plasma Cell 17Hematologic Neoplasms 17Leukemia, Myelomonocytic, Chronic 16Colorectal Neoplasms 16

Interventions

TIC10 compound 1Sorafenib 1Pemetrexed 1Imatinib Mesylate 1Cyclophosphamide 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Unspecified Adult Solid Tumor × Cyclophosphamide × Clear all
NCT00390156 2020-07-28

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

University of California, San Francisco

Phase 1 Completed
35 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡